Current Status of COVID-19 Outbreak and Vaccination in the Republic of Korea
1
조회
0
다운로드
4
인용
0
참고문헌
키워드
초록
Purpose: This study examines the current status of COVID-19 vaccination in the Republic of Korea. Therefore, we investigate the currently approved COVID-19 vaccines and their properties, COVID-19 vaccine prioritization guidance and timeline, and the status of adverse events after the COVID-19 vaccination. Moreover, we examine the SARS-CoV-2 variants and the current prevalent variants in the Republic of Korea. Method: This study was conducted on Web-based searches about the latest updates COVID-19 from the World Health Organization, Korea Centers for Disease Control and Prevention, and the Ministry of Food and Drug Safety. In addition, we searched for the “COVID-19 OR vaccines” in PubMed and then reviewed the selected articles re-garding COVID-19 vaccines, prioritization guidance, adverse effects, and variants. Results: To date, 4 COVID-19 vaccines have been received regulatory approval in the Republic of Korea. To promote stable COVID-19 vaccination, the COVID-19 Vaccination Promotion Task Force announced the order of COVID-19 vaccine distribution and vaccination schedules from the first and the third quarter of 2021, intending to complete the first dose of vaccination in 70% of the country's population by the end of September 2021. Currently, a total of 20,169,592 vaccine doses have been administered until August 02, 2021, representing 38.9% of the total population, and 7,289,659 individuals(about 14.1% of the country’s population) have been fully vaccinated so far. In total, 0.49%(105,937 cases) of individuals who were vaccinated reported adverse effects. Among them, 94.9% were general adverse reactions, and 5.1% were severe adverse effects, including death and suspected ana-phylaxis(severe allergic reactions). Recently, Delta variant is significantly expanding since June, and it is currently the predominant strain of the virus in the Republic of Korea. Conclusion: Since June 12, the highest Social Distancing Level 4 has been implemented in the Seoul Metropoli-tan Area. With COVID-19 vaccination, we need to cooperate with antivirus measures and cancel unnecessary so-cial gatherings to protect ourselves from the persistent infectious disease.
Abstract
Purpose: This study examines the current status of COVID-19 vaccination in the Republic of Korea. Therefore, we investigate the currently approved COVID-19 vaccines and their properties, COVID-19 vaccine prioritization guidance and timeline, and the status of adverse events after the COVID-19 vaccination. Moreover, we examine the SARS-CoV-2 variants and the current prevalent variants in the Republic of Korea. Method: This study was conducted on Web-based searches about the latest updates COVID-19 from the World Health Organization, Korea Centers for Disease Control and Prevention, and the Ministry of Food and Drug Safety. In addition, we searched for the “COVID-19 OR vaccines” in PubMed and then reviewed the selected articles re-garding COVID-19 vaccines, prioritization guidance, adverse effects, and variants. Results: To date, 4 COVID-19 vaccines have been received regulatory approval in the Republic of Korea. To promote stable COVID-19 vaccination, the COVID-19 Vaccination Promotion Task Force announced the order of COVID-19 vaccine distribution and vaccination schedules from the first and the third quarter of 2021, intending to complete the first dose of vaccination in 70% of the country's population by the end of September 2021. Currently, a total of 20,169,592 vaccine doses have been administered until August 02, 2021, representing 38.9% of the total population, and 7,289,659 individuals(about 14.1% of the country’s population) have been fully vaccinated so far. In total, 0.49%(105,937 cases) of individuals who were vaccinated reported adverse effects. Among them, 94.9% were general adverse reactions, and 5.1% were severe adverse effects, including death and suspected ana-phylaxis(severe allergic reactions). Recently, Delta variant is significantly expanding since June, and it is currently the predominant strain of the virus in the Republic of Korea. Conclusion: Since June 12, the highest Social Distancing Level 4 has been implemented in the Seoul Metropoli-tan Area. With COVID-19 vaccination, we need to cooperate with antivirus measures and cancel unnecessary so-cial gatherings to protect ourselves from the persistent infectious disease.
참고문헌 (41)
- Park IN, "Stepwise Strategy of Social Distancing in Korea", Journal of Korean Medical Science, 35(28), pp.1~6 (2020)
- 박균열, "COVID-19 and Some Implications to AI", Robotics & AI Ethics, 5(1), pp.16~24 (2020), J-INSTITUTE
- Kim D, "Government Roles of Policy Networks against Covid-19: Comparing Two Cases in S. Korea", Protection Convergence, 5(2), pp.14~26 (2020)
- 조홍제, "Human Security Task and Prospect on COVID-19 Pandemic", International Journal of Terrorism & National Security, 5(2), pp.48~55 (2020), J-INSTITUTE
- 박균열, "Virtue for Post COVID-19 and AI Technology", Robotics & AI Ethics, 5(2), pp.8~18 (2020), J-INSTITUTE
- 이상수, "Paradox of COVID-19 Pandemic, Strengthening Neo-Liberalist's Way of GLOBAL GOVERNANCE Building to Overcome Vaccine Nationalism's Politics", Regulations, 6(2), pp.1~9 (2021), J-INSTITUTE
- Carvalho T, "The First 12 Months of Covid-19: A Timeline of Immunological Insights", Nature Reviews Immunology, 21, pp.245~256 (2021)
- Xia S, "Fusion Mechanism of 2019-nCoV and Fusion Inhibitors Targeting HR1 Domain in Spike Protein", Cellular &43J-INSTITUTE.com Molecular Immunolgy, 17, pp.765~767 (2020)
- Angeli F, "SARS-CoV-2 Vaccines: Lights and Shadows", European Journal of Internal Medicine,, 88, pp.1~8 (2021)
- Voysey M, "Safety and Efficacy of the ChAdOx1 nCoV-19 Vaccine(AZD1222) against SARS-CoV-2: An Interim Analysis of Four Randomised Controlled Trials in Brazil, South Africa, and the UK", Lancet, 397, pp.99~111 (2021)
- WHO, "SAGE Values Framework for the Allocation and Prioritization of COVID-19 Vaccination", ~ (2020)
- Eun Bi Noh, "Which Group Should be Vaccinated First?: A Systematic Review", Infection and Chemotherapy, 53(2), pp.261~270 (2021), 대한감염학회[DOI]
- Turner PJ, "Covid-19Vaccine-associated Anaphylaxis: A Statement of the World Allergy Organization Anaphylaxis Committee", World Allergy Organ Journal,, 14, pp.100517~ (2021)
- Stone CA, "Immune-mediated Adverse Reactions to Vaccines", British Journal of Clinical Pharmacology, 85, pp.2694~2270 (2019)
- Kim Mi-Ae, "COVID-19 Vaccine-associated Anaphylaxis and Allergic Reactions: Consensus Statements of the KAAACI Urticaria", Angioedema, Allergy, Asthma & Immunology Research, pp.2021, 13(4)[DOI]
- Pormohammad A, "Efficacy and Safety of Covid-19 Vaccines: A Systematic Review and Meta-analysis of Randomized Clinical Trials", Vaccines(Basel), 9(5), pp.467~467 (2021)
- Oh H, "Status of Adverse Reactions after Covid-19 Vaccination in the Republic of Korea", Public Health Weekly Report,, 14(19), pp.1092~1098 (2021)
- Shaw RH, "Heterologous Prime-boost Covid-19 Vaccination: Initial Reactogenicity Data", Lancet, 397, pp.2043~2049 (2021)
- Lewis D, "Mix-and-match Covid Vaccines: The Case is Growing, but Questions Remain", Nautre, 595, pp.344~345 (2021)
- Gupta RK, "Will SARS-CoV-2 Variants of Concern Affect the Promise of Vaccines", Nature Reviews Immunology, 21, pp.340~341 (2021)
- Rambaut A, "A Dynamic Nomenclature Proposal for SARS-CoV-2 Lineages to Assist Genomic Epidemiology", Nature Microbiology, 5, pp.1403~1407 (2001)
- Sheikh A, "SARS-CoV-2 Delta VOC in Scotland: Demographics, Risk of Hospital Admission, and Vaccine Effectiveness", Lancet, 397, pp.2461~2462 (2021)
- Nasreen S, "ffectiveness of COVID-19 Vaccines against Variants of Concern in Ontario, Canata" (2021), MedRxiv
- Krause PR, "SARSCoV-2 Variants and Vaccines", New England Journal of Medicine, 385, pp.179~186 (2021)
- Zhou W, "Fast-spreading SARS-CoV-2 Variants: Challenges to and New Design Strategies of COVID-19 Vaccines", Signal Transduction and Targeted Therapy, 6, pp.226~226 (2021)
- Li Q, "Next-generation Covid-19 Vaccines: Opportunities for Vaccine Development and Challeges in Tackling Covid-19", Drug Discoveries & Therapeutics, 15(3), pp.118~123 (2021)